As companies move closer to completing a vaccine against the respiratory syncytial virus, a potentially very lucrative new market begins to emerge. It could even reach a size of USD 10.5bn in the next decade, estimates analyst at SVB Leerink Geoffrey Porges, according to Fiercepharma.
He thinks the well-established vaccine producers Glaxosmithkline, Pfizer and Johnson & Johnson will run with the biggest market share – respectively of USD 2.9bn, USD 2.1bn and USD 1.7bn by 2030.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.